Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. (Q53921466)

22 May 2018

title

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. (English)

1 reference

22 May 2018

borderline personality disorder

main subject

patient

0 references

0 references

author name string

S C Schulz

1

1 reference

22 May 2018

K L Camlin

2

1 reference

22 May 2018

S A Berry

3

1 reference

22 May 2018

J A Jesberger

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 November 1999

1 reference

22 May 2018

published in

Biological Psychiatry

1 reference

22 May 2018

volume

46

1 reference

22 May 2018

issue

10

1 reference

22 May 2018

page(s)

1429-1435

1 reference

22 May 2018

The schedule for Schizotypal Personalities (SSP): a diagnostic interview for schizotypal features

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

FACTOR ANALYSIS OF SOME PSYCHOMETRIC MEASURES OF IMPULSIVENESS AND ANXIETY.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Low-Dose Neuroleptic Regimens in the Treatment of Borderline Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Clozapine treatment of borderline patients: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Defining borderline patients: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

The diagnostic interview for borderline patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Pseudoneurotic forms of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Neuroleptic treatment of schizotypal personality disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Borderline personality organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Psychiatric diagnosis and a typology of clinical drug effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Cognitive-Behavioral Treatment of Chronically Parasuicidal Borderline Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Fluoxetine in the treatment of borderline and schizotypal personality disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Fluoxetine in borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Lithium Carbonate in Emotionally Unstable Character Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Efficacy of phenelzine and haloperidol in borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Paradoxical effects of amitriptyline on borderline patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Is there any drug treatment of choice for the borderline patient?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(99)00128-6

1 reference

22 May 2018

1 reference

22 May 2018